Teneliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD40 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
299423-37-3  |
| ChemSpider | none |
| UNII |
G0MV33WQ6V  |
| KEGG |
D06071 |
| (what is this?) (verify) | |
Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40. As of 2009, it has not entered clinical trials.[2]
References
- ↑ International Nonproprietary Names For Pharmaceutical Substances
- ↑ Iqbal S. Grewal, ed. (January 15, 2009). Therapeutic Targets of the TNF Superfamily (Advances in Experimental Medicine and Biology). Springer. p. 22. ISBN 0-387-89519-1.
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.